SPI 1620

Drug Profile

SPI 1620

Alternative Names: IRL-1620; SPI-1620

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator University of Illinois at Chicago
  • Developer Spectrum Pharmaceuticals
  • Class Antineoplastics; Peptides; Vasodilators
  • Mechanism of Action Endothelin B receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Biliary cancer; Solid tumours

Highest Development Phases

  • Phase II Biliary cancer; Non-small cell lung cancer
  • Phase I Solid tumours

Most Recent Events

  • 20 Jul 2016 Spectrum Pharmaceuticals terminates its phase II trial for Non-small cell lung cancer (late-stage disease, second-line therapy or greater, combination therapy) in USA as the trial did not meet its primary endpoint (NCT01741155)
  • 20 Jul 2016 Spectrum Pharmaceuticals terminates its phase II trial for Biliary cancer (adjunctive treatment, late-stage disease, second-line therapy or greater) in USA as the trial did not meet its primary endpoint (IV) (NCT01773785)
  • 31 May 2013 Phase-II clinical trials in Non-small cell lung cancer (late-stage disease, second-line therapy or greater, combination therapy) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top